Skip to main content
Skip to main menu Skip to spotlight region Skip to secondary region Skip to UGA region Skip to Tertiary region Skip to Quaternary region Skip to unit footer


BMB Fall Mini-Symposium: Cancer Immunotherapy

CCRC Auditorium

Chrystal Paulos, Ph.D.

Associate Professor, Department of Microbiology and Immunology

Hollings Cancer Center

Medical University of South Carolina

“Enhancing T cell Therapy for Cancer”

Dr. Paulos' research focuses on the potential role of human IL-17 producing cells in tumor immunity. Currently, Dr. Paulos' laboratory is investigating how ICOS signaling modulates key transcription factors that impact the function fate of inflammatory Th17/Tc17 cells and the mechanisms governing the effectiveness of ICOS-expanded Th17/Tc17 cells using a highly clinically relevant cancer mouse model.


Steven Almo, Ph.D.

Professor and Chair, Department of Biochemistry

Albert Einstein College of Medicine

“Clonal Selective T Cell Modulation”

Our high-resolution structural and functional analysis of the mammalian immune system has resulted in unprecedented understanding of the molecular mechanisms that control immunity and are guiding the development of novel strategies and reagents (e.g., biologics) for the treatment of infectious diseases, autoimmune diseases and cancers.


Juan Cubillos-Ruiz, Ph.D.

Assistant Professor of Microbiology & Immunology, Weill Cornell Medical College

Scientific Co-Founder and Advisor, Quentis Therapeutics, Inc

“Stress Management in Intratumoral Immune Cells”

Research in the Cubillos-Ruiz lab aims at understanding how Endoplasmic Reticulum (ER) stress responses sculpt immune cell function in health and disease.  Our lab focuses on uncovering and characterizing the immunometabolic and epigenetic programs controlled by ER stress in cancer, pain and infectious diseases.   We also have a particular interest in developing new cancer immunotherapies based on targeting aberrant ER stress responses in the tumor microenvironment.


Marianne Stanford, Ph.D.

Vice President, Research and Development of IMV, Inc.

Assistant Professor, Department of Microbiology and Immunology, Dalhousie University

“How Do We Effectively Target T cells to Tumors?”

IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin.

Support us

We appreciate your financial support. Your gift is important to us and helps support critical opportunities for students and faculty alike, including lectures, travel support, and any number of educational events that augment the classroom experience. Click here to learn more about giving.

Every dollar given has a direct impact upon our students and faculty.